SLC5A2 and intestinal obstruction: The principal findings are that high-dose canagliflozin (300 mg/day) is associated with an increased risk of intestinal obstruction, whereas liraglutide appears to confer a reduced risk, and no other GLP-1 receptor agonist or SGLT2 inhibitor was linked to a statistically significant increase in obstruction events.